Wednesday, May 6, 2026

North Korea’s Corruption Crisis: How Kim Jong Un’s ‘Self-Reliance’ Policy is Threatening Regime Stability

North Korea's self-reliance policy has increased corruption among officials, threatening Kim Jong Un's regime stability ahead of the 9th Party Congress.

Why 80% of Companies Want to Reopen Kaesong Industrial Complex: A Deep Dive into the Benefits

Reopening the Kaesong Industrial Complex could enhance inter-Korean relations, with 80% of former companies eager to return.

J-Hope’s New Remix Album Promises a Sonic Adventure

J-Hope will release "Sweet Dreams - zzZ Remixes," featuring six tracks, including various remixes of his hit song "Sweet Dreams."

Jin Joong Hwang

Author's Latest

How SK Bioscience Plans to Dominate the Global Vaccine Market in 2026

SK Bioscience enhances its operational system with new COO and key appointments to boost global competitiveness and vaccine development.

Botox Faces New Challenger: Chong Kun Dang’s Toxin Shows Non-Inferiority in China Study

Chong Kun Dang's CKDB-501A shows non-inferiority to Botox in Phase 3 trials for treating glabellar lines, with promising safety data.

NK Cell Cancer Therapies Move Closer to Market as Matica BioLabs Partners With Ingenium

CHA Biotech's Matica BioLabs partners with Ingenium Therapeutics for NK cell therapy production, targeting cancer treatment advancements.

ABL206: First-in-Class Dual Antibody Drug Conjugate Approved for Clinical Trials in the U.S. – What This Means for Cancer Treatment

ABL Bio and Neok Bio received FDA approval for ABL206, a dual-antibody ADC, marking a key milestone in their clinical development efforts.

K-Bio Revolution: How Korean Biopharmaceuticals Are Conquering the Global Market in 2026

South Korea's pharmaceutical industry thrives with innovative drugs like botulinum toxins and cancer treatments, targeting global markets.

Samsung Bioepis Secures U.S. Approval for Pen-Style Stelara Biosimilar, Setting a Market First

Samsung Bioepis receives FDA approval for Epyztek, the first pre-filled pen for autoimmune treatments, enhancing patient convenience.

Chong Kun Dang Wins European Phase 1 Approval for Dupixent Biosimilar: Advancing CKD-706’s Global Development

Chong Kun Dang's CKD-706 biosimilar for Dupixent received Phase 1 trial approval in Europe, aiming to expand treatment options for inflammatory diseases.

K-Bio Targets the U.S. Market: Celltrion and Samsung Bioepis Close in on Originator Drugs

Celltrion and Samsung Bioepis are expanding in the U.S. market, showing strong growth in biosimilars like Zymfentra and Hadlima.

How Ecrac Gel is Revolutionizing Axillary Hyperhidrosis Treatment in Korea: What You Need to Know

Dongwha Pharmaceutical launched Ecrac Gel, Korea's first prescription for underarm hyperhidrosis, promising effective relief for patients.

Unlocking Convenience: Rolvedon’s Same-Day Chemotherapy Solution for Neutropenia Revealed

Hanmi Pharmaceutical's Rolvedon shows potential for same-day chemotherapy administration, improving patient convenience and market competitiveness.

Is RPG-102 the Future of Obesity Treatment? Discover the Breakthrough Oral Solution!

ProGen and Rani Therapeutics initiate a Phase 1 trial for RPG-102, an oral obesity treatment, aiming for effective weight loss with weekly dosing.

HK inno.N’s New Drug K-CAB Applies for U.S. FDA Approval: How Innovative Is the P-CAB Therapy?

HK inno.N's K-Cap for GERD has entered the U.S. approval process, showing superior results in clinical trials over existing treatments.

How Neurophet AQUA is Transforming Dementia Diagnosis in South Korea: Key MOU Insights

Neurophet partners with Eisai Korea to enhance dementia screening and diagnostics using AI-based software, Neurophet AQUA.

Revolutionizing Kidney Stone Surgery: Roen Surgical’s AI Robot Zamenix Launches in Indonesia

Roen Surgical exports AI-powered kidney stone surgery robot Zamenix to Indonesia, enhancing surgical precision and safety in healthcare.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.